Literature DB >> 29189508

Steroid-induced Hypertension During Induction Chemotherapy for Acute Lymphoblastic Leukemia in US Children's Hospitals.

Ian Bakk1, Terah Koch2, Joseph Stanek2, Sarah H O'Brien3, Suzanne Reed3.   

Abstract

Childhood acute lymphoblastic leukemia achieves excellent cure rates in part due to induction chemotherapy including high dose corticosteroids. Hypertension (HTN) is a known complication of corticosteroids, but incidence and risk factors for steroid-induced HTN are poorly understood. We sought to describe these using a large pediatric health database. Of the 5578 unique patients receiving induction chemotherapy, 14.7% received anti-HTN medications during their initial hospital admission. We found that age below 1 year, obesity, secondary diabetes mellitus, and abnormal glucose were associated with developing steroid-induced HTN. We also found that ICD-9 codes had poor sensitivity for detecting treatment of HTN, suggesting underreporting by physicians.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29189508     DOI: 10.1097/MPH.0000000000000997

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  Hypertension is a modifiable risk factor for osteonecrosis in acute lymphoblastic leukemia.

Authors:  Laura J Janke; Sara L Van Driest; Mary V Portera; Ravi V Atreya; Joshua C Denny; Deqing Pei; Cheng Cheng; Sue C Kaste; Hiroto Inaba; Sima Jeha; Ching-Hon Pui; Mary V Relling; Seth E Karol
Journal:  Blood       Date:  2019-08-13       Impact factor: 22.113

Review 2.  Hypertension in Pediatric Acute Lymphoblastic Leukemia Patients: Prevalence, Impact, and Management Strategies.

Authors:  Lindsey Murphy; Kelly Maloney; Lia Gore; Eliza Blanchette
Journal:  Integr Blood Press Control       Date:  2022-01-19

3.  Supportive methods for childhood acute lymphoblastic leukemia then and now: A compilation for clinical practice.

Authors:  Alexandra Podpeskar; Roman Crazzolara; Gabriele Kropshofer; Petra Obexer; Evelyn Rabensteiner; Miriam Michel; Christina Salvador
Journal:  Front Pediatr       Date:  2022-09-12       Impact factor: 3.569

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.